ASX Announcement

Starpharma and Peter Mac Cancer Centre awarded DEP® Grant

Melbourne, Australia; 9 October 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) and Peter MacCallum Cancer Centre (Peter Mac) have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma's DEP® oncology program.

Starpharma's proprietary DEP® dendrimer platform improves efficacy and reduces off-target toxicity to improve therapeutic outcomes for cancer patients. Oncology therapeutic agents are commonly used in combination to achieve optimal impact on cancer cells. This $50,000 of funding will be used to assess sophisticated new and existing DEP® candidates in combination with existing therapeutic agents.

Starpharma CEO, Dr Jackie Fairley, commented "Peter MacCallum Cancer Centre has been an outstanding long-time collaborator for Starpharma and we are delighted to continue our work with Dr Carleen Cullinane and her expert team in translational research. This work could generate important data aimed at improving treatment regimens and further enhances commercialisation opportunities for Starpharma's DEP® technology. This Federal Government funding helps to build critical partnerships between commercial enterprises and the research sector."

Dr Carleen Cullinane, Co-Head of Peter Mac's Translational Research Lab said, "We are enthusiastic to work with Starpharma to develop DEP® dendrimer drug delivery combinations. The Innovation Connections grant program is supporting exciting innovative technology to have the greatest patient impact."

About the Innovation Connections program

The Federal Government's Innovation Connections program provides small and medium sized businesses with support to collaborate with the research sector in developing new ideas with commercial potential.

About Peter MacCallum Cancer Centre

Peter Mac is one of the world's leading cancer research, education and treatment centers globally and is Australia's only public hospital solely dedicated to caring for people affected by cancer. Peter Mac is focused on providing better treatments, better care and potential cures for cancer. Peter Mac's comprehensive and internationally renowned cancer laboratories seek fundamental biological and biomedical discoveries, and aim to facilitate the development and application of these discoveries to their full therapeutic potential.

VivaGel®: Starpharma's portfolio includes late stage women's health products based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer. VivaGel® formulated as a water based gel and delivered vaginally - VivaGel® BV - has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and has recently completed clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand. Starpharma has also developed an antiviral condom which uses VivaGel® in the lubricant. The VivaGel® condom is available in Australia and Canada under the Lifestyles® Dual Protect™ brand and Starpharma also has a number of license agreements to market the VivaGel® condom in other regions, including China and Japan.

DEP®: The other major part of Starpharma's pharmaceuticals business is its proprietary DEP® drug delivery platform. Starpharma has both partnered and internal DEP® programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development by the Company. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). In the partnered area, AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of a number of AstraZeneca oncology compounds.

Starpharma.com | Twitter | LinkedIn

Media
WE Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.